UBS upgraded Medacta Group to Buy from Neutral with a price target of CHF 137, up from CHF 119. Medacta’s unique focus on niche segments has driven 3-5x orthopedic growth and this should continue in 2024-2024, warranting a 35%-40% premium to the sector, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue